AP2238 - CAS 553681-56-4
Catalog number: 553681-56-4
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
AP2238 is a inhibitor of both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Solid powder
AP-2238;2H-1-Benzopyran-2-one, 6,7-dimethoxy-3-(4-((methyl(phenylmethyl)amino)methyl)phenyl)-;3-[4-(N-Benzyl-N-methylaminomethyl)phenyl]-6,7-dimethoxy-2H-1-benzopyran-2-one
Soluble in DMSO, not in water
-20°C Freezer
Quality Standard:
In-house standard
Boiling Point:
568.9±50.0 °C | Condition: Press: 760 Torr
1.205±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
Canonical SMILES:
1.From the dual function lead AP2238 to AP2469, a multi-target-directed ligand for the treatment of Alzheimer's disease.
Tarozzi A;Bartolini M;Piazzi L;Valgimigli L;Amorati R;Bolondi C;Djemil A;Mancini F;Andrisano V;Rampa A Pharmacol Res Perspect. 2014 Apr;2(2):e00023. doi: 10.1002/prp2.23. Epub 2014 Mar 24.
The development of drugs with different pharmacological properties appears to be an innovative therapeutic approach for Alzheimer's disease. In this article, we describe a simple structural modification of AP2238, a first dual function lead, in particular the introduction of the catechol moiety performed in order to search for multi-target ligands. The new compound AP2469 retains anti-acetylcholinesterase (AChE) and beta-site amyloid precursor protein cleaving enzyme (BACE)1 activities compared to the reference, and is also able to inhibit Aβ 42 self-aggregation, Aβ 42 oligomer-binding to cell membrane and subsequently reactive oxygen species formation in both neuronal and microglial cells. The ability of AP2469 to interfere with Aβ 42 oligomer-binding to neuron and microglial cell membrane gives this molecule both neuroprotective and anti-inflammatory properties. These findings, together with its strong chain-breaking antioxidant performance, make AP2469 a potential drug able to modify the course of the disease.
2.Multitarget Strategy to Address Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and Computational Studies of Coumarin-Based Derivatives.
Montanari S;Bartolini M;Neviani P;Belluti F;Gobbi S;Pruccoli L;Tarozzi A;Falchi F;Andrisano V;Miszta P;Cavalli A;Filipek S;Bisi A;Rampa A ChemMedChem. 2016 Jun 20;11(12):1296-308. doi: 10.1002/cmdc.201500392. Epub 2015 Oct 28.
Alzheimer's disease (AD) is a major public health challenge that faces an aging global population. Current drug treatment has demonstrated only symptomatic efficacy, leaving an unmet medical need for a new generation of disease-modifying therapies. Following the multitarget-directed ligand approach, a small library of coumarin-based derivatives was designed and synthesized as a follow-up to our studies on AP2238, aimed at expanding its biological profile. The coumarin substitution pattern at the 6- or 7-position was modified by introducing alkyl chains of variable lengths and with different terminal amino functional groups. 3-(4-{[Benzyl(ethyl)amino]methyl}phenyl)-6-({5-[(7-methoxy-6H-indeno[2,1-b]quinolin-11-yl)amino]pentyl}oxy)-2H-chromen-2-one, bearing the bulkiest amine, emerged as a non-neurotoxic dual acetylcholinesterase (AChE)/butyrylcholinesterase (BuChE) inhibitor, potentially suitable for the treatment of the middle stage of AD. Furthermore, the introduction of a diethylamino spacer, as in 3-(4-{[benzyl(ethyl)amino]methyl}phenyl)-6-{[5-(diethylamino)pentyl]oxy}-2H-chromen-2-one and 3-(4-{[benzyl(ethyl)amino]methyl}phenyl)-7-[4-(diethylamino)butoxy]-2H-chromen-2-one, led to nanomolar human AChE inhibitors endowed with significant inhibitory activity toward Aβ42 self-aggregation, whereas the reference compound was completely ineffective.
3.Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds.
Piazzi L;Cavalli A;Colizzi F;Belluti F;Bartolini M;Mancini F;Recanatini M;Andrisano V;Rampa A Bioorg Med Chem Lett. 2008 Jan 1;18(1):423-6. Epub 2007 Oct 4.
The complex etiology of Alzheimer's disease (AD) prompts scientists to develop multifunctional compounds to combat causes and symptoms of such neurodegeneration. To this aim we designed, synthesized, and tested a series of compounds by introducing halophenylalkylamidic functions on the scaffold of AP2238, which is a dual binding site acetylcholinesterase inhibitor. The inhibitory activity was successfully extended to the beta-site amyloid precursor protein cleavage enzyme, leading to the discovery of a potent inhibitor of this enzyme (3) and affording multifunctional compounds (2, 6, 8) for the treatment of AD.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related AChE Products

CAS 51-15-0 Pralidoxime chloride

Pralidoxime chloride
(CAS: 51-15-0)

Pralidoxime is an antidote to organophosphate pesticides, reactivates the enzyme cholinesterase by cleaving the phosphate-ester bond formed between the organoph...

CI 1002
(CAS: 149028-28-4)

CI 1002, an azepinoquinazoline derivative, has been found to be an acetylcholinesterase inhibitor that could probably be effective against cognitive dysfunction...

CAS 13473-38-6 Pipenzolate

(CAS: 13473-38-6)

Pipenzolate, a muscarinic receptor antagonist, commonly existed as bromide salt form and could be used as a spasmolytic and could probably effective in aid ther...

CAS 1192750-33-6 PE 154

PE 154
(CAS: 1192750-33-6)

PE 154 is a fluorescent inhibitor of both AChE and BChE with IC50 values of 280 pM and 16 nM. PE 154 targets and labels β-amyloid plaques in histochemical analy...

CAS 209394-46-7 Ladostigil tartrate

Ladostigil tartrate
(CAS: 209394-46-7)

Ladostigil, also called as TV-3,326, is a novel neuroprotective agent developed to treat neurodegenerative disorders sunch as Alzheimer’s disease. Ladostigil is...

CAS 1684-40-8 Tacrine hydrochloride

Tacrine hydrochloride
(CAS: 1684-40-8)

Tacrine hydrochloride is a potent cholinesterase inhibitor used for the treatment of memory deficits in patients with Alzheimers's disease. Tacrine hydrochlorid...

CAS 123441-03-2 Rivastigmine

(CAS: 123441-03-2)

Rivastigmine, a carbamate derivative, is a reversible cholinesterase inhibitor that is selective for the central nervous system to treat Alzheimer's Disease.

CAS 314-03-4 Pimethixene

(CAS: 314-03-4)

Pimethixene, also called as BP 400 or Calmixène, with antihistamine and anticholinergic properties it treats hyperactivity, anxiety, sleep disorders, and allerg...

Quick Inquiry

Verification code

Featured Items